Alpine Immune Sciences Inc (ALPN)
64.60
+0.07
(+0.11%)
USD |
NASDAQ |
Apr 24, 13:01
Alpine Immune Sciences Net Income (Quarterly): 5.96M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 5.96M |
September 30, 2023 | -11.72M |
June 30, 2023 | -13.16M |
March 31, 2023 | -13.27M |
December 31, 2022 | -18.86M |
September 30, 2022 | -13.27M |
June 30, 2022 | -18.10M |
March 31, 2022 | -7.527M |
December 31, 2021 | -15.17M |
September 30, 2021 | -13.49M |
June 30, 2021 | -11.03M |
March 31, 2021 | -10.64M |
December 31, 2020 | -6.342M |
September 30, 2020 | -6.137M |
June 30, 2020 | -9.928M |
March 31, 2020 | -5.533M |
December 31, 2019 | -6.14M |
September 30, 2019 | -11.48M |
June 30, 2019 | -11.86M |
March 31, 2019 | -12.38M |
Date | Value |
---|---|
December 31, 2018 | -11.14M |
September 30, 2018 | -12.14M |
June 30, 2018 | -7.907M |
March 31, 2018 | -5.306M |
December 31, 2017 | -4.318M |
September 30, 2017 | 2.122M |
June 30, 2017 | -3.71M |
March 31, 2017 | -8.916M |
December 31, 2016 | -7.713M |
September 30, 2016 | -7.433M |
June 30, 2016 | -8.479M |
March 31, 2016 | -7.838M |
December 31, 2015 | -6.563M |
September 30, 2015 | -6.089M |
June 30, 2015 | -5.852M |
March 31, 2015 | -4.314M |
December 31, 2014 | -3.486M |
September 30, 2014 | -3.011M |
June 30, 2014 | -4.189M |
March 31, 2014 | -4.350M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-18.86M
Minimum
Dec 2022
5.96M
Maximum
Dec 2023
-10.40M
Average
-11.48M
Median
Sep 2019
Net Income (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 968.80M |
Vera Therapeutics Inc | -25.66M |
Eliem Therapeutics Inc | -3.641M |
Regeneron Pharmaceuticals Inc | 1.160B |
Eyenovia Inc | -7.967M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 30.85M |
Total Expenses (Quarterly) | 29.31M |
EPS Diluted (Quarterly) | 0.15 |
Enterprise Value | 3.902B |
Profit Margin (Quarterly) | 19.32% |
Earnings Yield | -0.99% |
Normalized Earnings Yield | -0.9907 |